| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/23/2006 | CN1270708C Medicinal composition for treating interstitial cystitis |
| 08/23/2006 | CN1270634C Soft capsule of dried oviduct fat of forest frog |
| 08/22/2006 | US7094930 Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| 08/22/2006 | US7094916 vitamin D3 derivative as anti-cancer agent, for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion, for immune disorders, metabolic bone diseases and also used as antiinflammatory agent |
| 08/22/2006 | US7094877 Protein for use in treatment of inflammation, nervous system, pain, arthritic and skin disorders |
| 08/22/2006 | US7094805 Total synthesis of merrilactone A |
| 08/22/2006 | US7094802 PKB-3564 substance with neovascularization inhibitory activity |
| 08/22/2006 | US7094787 Compositions for regulating desire for smoking |
| 08/22/2006 | US7094781 Sulfamides and their use as endothelin receptor antagonists |
| 08/22/2006 | US7094779 2-(3-indolylmethyl)-1-benzoyl-4-oxime-piperazine derivatives, e.g., 1-{(2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(1H-indol-3-ylmethyl)-piperazin-4-yl}-2-propanone O-[2-(dimethylamino)-ethyl]oxime, used for treatment of CNS disorders. |
| 08/22/2006 | US7094776 cyclohexane ring is 3,5-dihydroxy-substituted and 2,4-alkylene-bridged; treating metabolic bone disease including senile, postmenopausal, and steroid-induced osteoporosis, osteomalacia, renal osteodystrophy and rickets |
| 08/22/2006 | US7094427 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 08/22/2006 | US7094392 Heating antihistamine drug vaporize; cooling to form a condensation aerosol; kit for dispensing thin coating |
| 08/17/2006 | WO2006086734A1 Substituted propane phosphinic acid esters |
| 08/17/2006 | WO2006086464A2 Dihydroquinazolinones as 5ht modulators |
| 08/17/2006 | WO2006086452A1 Methods for treating visual disorders |
| 08/17/2006 | WO2006086229A1 The use of selective p2x7 receptor antagonists |
| 08/17/2006 | WO2006085697A1 Combination therapy for cerebrovascular disease using adrenomedulin with mesenchymal stem cell |
| 08/17/2006 | WO2006085692A1 Crystal of 4(3h)-quinazolinone derivative |
| 08/17/2006 | WO2006085688A1 Psychogenic pain therapeutic agent |
| 08/17/2006 | WO2006085686A1 Remedy for neurogenic pain |
| 08/17/2006 | WO2006085648A1 Novel narcolepsy-related gene |
| 08/17/2006 | WO2006085612A1 Method for preparation of neural stem cells |
| 08/17/2006 | WO2006085587A1 Neurosphere-forming agent |
| 08/17/2006 | WO2006085497A1 Tablet disintegrating in the oral cavity |
| 08/17/2006 | WO2006085216A1 Substituted hydroxyethylamines |
| 08/17/2006 | WO2006084975A1 Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, thiourea and urea) as cannabinoid cb1 receptor antagonists |
| 08/17/2006 | WO2006084934A1 Use of thiadiazolidine-derived compounds as neurogenic agents |
| 08/17/2006 | WO2006084894A2 Use of tryptophan in combination with caffeine and taurine, foodstuff and beverage containing said combination |
| 08/17/2006 | WO2006084854A2 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular |
| 08/17/2006 | WO2006084833A1 Monohydrochloride salt of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine |
| 08/17/2006 | WO2006084782A1 Use of iron(iii) complex compounds |
| 08/17/2006 | WO2006084765A1 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency |
| 08/17/2006 | WO2006084683A1 Methods for improving drug disposition |
| 08/17/2006 | WO2006084368A1 Fluorinated phno and analogs thereof |
| 08/17/2006 | WO2006084333A1 Neuroprotective agents and methods of their use |
| 08/17/2006 | WO2006084322A1 Treatment method for modifying tissue passive electrical conductance |
| 08/17/2006 | WO2006071995A9 Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
| 08/17/2006 | WO2006071778A3 Treatment of parkinson's disease and related disorders using postpartum derived cells |
| 08/17/2006 | WO2006071601A3 Therapeutic compositions for intranasal administration of ketorolac |
| 08/17/2006 | WO2006059252A3 Methods and fluorinated compositions for treating amyloid-related diseases |
| 08/17/2006 | WO2006052768A3 Process for preparing quinoline compounds and products obtained therefrom |
| 08/17/2006 | WO2006046135A3 Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors |
| 08/17/2006 | WO2006044753A3 Chemical compounds |
| 08/17/2006 | WO2006026533A8 Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors |
| 08/17/2006 | WO2006005707A3 Method for preventing and treating alzheimer´s disease |
| 08/17/2006 | WO2005123068A3 Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
| 08/17/2006 | WO2005102389A3 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists |
| 08/17/2006 | WO2005097140A3 Selective antagonists of a2a adenosine receptors |
| 08/17/2006 | WO2003088904A3 Screening and therapeutic methods for treating circadian rhythm disorders |
| 08/17/2006 | WO2003066071A8 Formulations comprising psychotropic drugs and selenium |
| 08/17/2006 | WO2003053346A3 Systems and methods for treating patients with processed lipoaspirate cells |
| 08/17/2006 | US20060185026 Atypical protein kinase c isoforms in disorders of the nervous system and cancer |
| 08/17/2006 | US20060183921 Pharmaceutically active compounds and methods of use |
| 08/17/2006 | US20060183909 Compositions derived from quinoline and quinoxaline, preparation and use thereof |
| 08/17/2006 | US20060183805 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof |
| 08/17/2006 | US20060183798 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| 08/17/2006 | US20060183797 Fatty alcohols and fatty acid esters useful for treatment of inflammation |
| 08/17/2006 | US20060183795 Use of a monocarbamate enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein a monocarbamate enantiomer predominates in preventing or treating neuropathic pain |
| 08/17/2006 | US20060183791 Substituted p-diaminobenzene derivatives |
| 08/17/2006 | US20060183784 Human growth hormone antagonists |
| 08/17/2006 | US20060183775 Using N((1-(2-(4-hydroxyphenyl)ethyl)-4-piperidinyl)methyl)-1-isopropyl-1H-indazole-3-carboxamide hydrochloride to treat neuropathic pain caused by trauma, multiple sclerosis, immunodeficiency; ischemia, diabetes and neuralgia |
| 08/17/2006 | US20060183774 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 08/17/2006 | US20060183770 Sulfonamide derivative having isoxazole ring |
| 08/17/2006 | US20060183760 (2S3R)-3-{9-Isopropyl-6-[(pyridin-2-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative; cancer, leukemia, psoriasis; cyclin-dependent kinase (CDK) inhibitors |
| 08/17/2006 | US20060183757 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 08/17/2006 | US20060183739 Carbonyl compounds |
| 08/17/2006 | US20060183732 Novel lactams and uses thereof |
| 08/17/2006 | US20060183695 Methods of increasing endogenous erythropoietin (EPO) |
| 08/17/2006 | US20060183192 Modulation of sodium channels in dorsal root ganglia |
| 08/17/2006 | US20060183160 Novel beta-secretase and modulation of beta-secretase activity |
| 08/17/2006 | US20060183105 Human brain-derived tissue-specific potassium channel |
| 08/17/2006 | US20060182817 Steroidal sapogenins and their derivatives for treating Alzheimer's disease |
| 08/17/2006 | US20060182801 Sequestered antagonist formulations |
| 08/17/2006 | US20060182715 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-ss |
| 08/17/2006 | CA2597798A1 Fluorinated phno and analogs thereof |
| 08/17/2006 | CA2597574A1 Substituted hydroxyethylamines |
| 08/17/2006 | CA2597541A1 Crystal of 4(3h)-quinazolinone derivative |
| 08/17/2006 | CA2597523A1 [1,2,4]-dithiazoli(di)ne derivatives, inducers of gluthathione-s-transferase and nadph quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated withcytotoxicity in general and apoptosis in particular |
| 08/17/2006 | CA2597408A1 Substituted propane phosphinic acid esters |
| 08/17/2006 | CA2597335A1 Neuroprotective agents and methods of their use |
| 08/17/2006 | CA2597332A1 Methods for improving drug disposition |
| 08/17/2006 | CA2597101A1 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency |
| 08/17/2006 | CA2597016A1 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine |
| 08/17/2006 | CA2596613A1 Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, thiourea and urea) as cannabinoid cb1 receptor antagonists |
| 08/17/2006 | CA2594405A1 Biomarkers and uses thereof |
| 08/17/2006 | CA2593497A1 Amorphous ziprasidone mesylate |
| 08/16/2006 | EP1690864A2 Tricyclic purine compounds and their analogs as inhibitors of cytokine signalling |
| 08/16/2006 | EP1690861A2 A process for preparing duloxetine and intermediates for use therein |
| 08/16/2006 | EP1690858A1 Monohydrochloride salt of 1-¬3-¬3-(4-chlorophenyl)propoxy|propyl|-piperidine |
| 08/16/2006 | EP1690857A1 Modified-protein formation inhibitor |
| 08/16/2006 | EP1690852A1 Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto |
| 08/16/2006 | EP1690547A1 Prevention and treatment of amyloidogenic disease |
| 08/16/2006 | EP1690541A1 Use of a sodium channel blocker and their analogues for the treatment of nicotine dependency |
| 08/16/2006 | EP1690540A1 Composition comprising ocaperidone |
| 08/16/2006 | EP1690538A1 Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor |
| 08/16/2006 | EP1689742A1 Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
| 08/16/2006 | EP1689740A1 Pyrazolyl and imidazolyl pyrimidines |
| 08/16/2006 | EP1689737A1 Beta-lactams for the treatment of cns disorders |
| 08/16/2006 | EP1689730A1 Gsk-3 inhibitors isolated from marine organisms |